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Abstract
Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder associated with allergic 
hypersensitivity to food. We interrogated >1.5 million genetic variants in European EoE cases and 
subsequently in a multi-site cohort with local and out-of-study control subjects. In addition to 
replication of the 5q22 locus (meta-analysis p = 1.9×10−16), we identified association at 2p23 
(encoding CAPN14, p = 2.5×10−10). CAPN14 was specifically expressed in the esophagus, 
dynamically upregulated as a function of disease activity and genetic haplotype and after exposure 
of epithelial cells to IL-13, and located in an epigenetic hotspot modified by IL-13. There was 
enriched esophageal expression for the genes neighboring the top 208 EoE sequence variants. 
Multiple allergic sensitization loci were associated with EoE susceptibility (4.8×10−2 < p < 
5.1×10−11). We propose a model that elucidates the tissue specific nature of EoE that involves the 
interplay of allergic sensitization with an EoE-specific, IL-13–inducible esophageal response 
involving CAPN14.
Eosinophilic esophagitis (EoE) is a chronic, food antigen–driven, tissue-specific, 
esophageal, inflammatory disease characterized by marked mucosal eosinophil 
accumulation that is often associated with fibrosis, stricture formation, and impaired 
motility1–4. The disease remits after removal of specific food types, reoccurs upon food re-
introduction, is associated with marked dysregulation of esophageal transcripts rich in 
elements involved in allergic inflammation and can be induced in mice by allergen exposure 
through IL-5– and IL-13–driven pathways5–8. Consistent with an allergic etiology, EoE 
frequently co-occurs with allergic diseases including asthma, eczema and food 
anaphylaxis2–4. Why EoE patients develop a tissue-specific response remains an enigma, as 
the currently identified inflammatory pathways and genes in EoE and other allergic diseases 
overlap.
The only EoE genome-wide association study (GWAS) reported to date identified a single 
significant susceptibility locus at 5q22, which harbors the gene for thymic stromal 
lymphopoietin, TSLP9. A candidate gene analysis confirmed the association of EoE with 
TSLP, as well as its receptor CRLF2 (cytokine receptor-like factor 2)10,11. Candidate gene 
studies have shown that CCL26 (eotaxin 3) and FLG (filaggrin)12,13 are associated with EoE 
susceptibility. However, genetic variations in these genes and 5q22 have also been linked 
with other atopic disorders14–16, highlighting the need to elucidate how genetics may 
contribute to the tissue specificity of this disorder.
Accordingly, we performed a GWAS of single-nucleotide polymorphisms (SNPs) from >1.5 
million genetic markers. This GWAS greatly expanded the number of EoE cases (from 351 
to 736) and controls (from 3105 to 9246) of the previous study. Combined genetic 
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association analysis identified 20 SNPs at 17 loci (threshold p < 10−7). Ten of these loci 
were identified in the analysis of our Cincinnati Children’s Hospital Medical Center 
(CCHMC) cohort (p < 10−4) and in an analysis in which the external controls were excluded 
(p < 5×10−2) and also independently confirmed in the NIH Consortium of Food Allergy 
Research (CoFAR) cohort (p < 5×10−2; Table 1, Figure 1, Supplementary Tables 1 and 2, 
Supplementary Figure 1). This series of consistency checks was used to reduce the chance of 
false positives due to the inclusion of an external control cohort.
Markers in 2p23, 5q22, 8p23, and 15q13 reached genome-wide significance (p < 5×10−8). 
The variants most highly associated with increased risk of EoE were found at 2p23 spanning 
the CAPN14 gene (best SNP rs77569859, p = 3.30×10−10, odds ratio [OR]=1.98) (Table 1). 
In order to identify the commonly occurring variants (minor allele frequency [MAF] > 1%) 
on the risk haplotype that could be driving the genetic association, we imputed this region to 
a composite reference panel from 1,000 genomes17,18; no haplotype of continuous SNPs or 
haplotype constructed using the most associated variants in the region was more highly 
associated with EoE risk than rs77569859 alone (best haplotype p = 3.5×10−8, OR = 1.6; 
Figure 1b and data not shown). Variants at the other two newly discovered loci reaching 
genome-wide significance were located at the XKR6 (XK, Kell blood group complex 
subunit-related family, member 6) gene (8p23) and in a gene desert (15q13). Very little is 
known about XKR6; however, public expression databases report expression in the immune 
compartment (Supplementary Figure 2). These four genome-wide susceptibility loci 
remained associated with EoE, and the effect size was not significantly influenced after 
correcting for atopy (Supplementary Table 3).
Using an independently ascertained cohort that did not overlap with the first EoE GWAS9, 
there was strong replication of disease linkage with 5q22 (rs6594499, Fishers combined p = 
1.9×10−16; Supplementary Table 4). After imputing the region, the most significant 
association with the development of EoE was downstream of TSLP and WDR36 at 
rs1438672 (Figure 1C), with 12 variants having a p < 10−2 (p between 0.001 and 0.05) after 
adjusting for the most significant variant. After accounting for multiple testing, we cannot 
reject the null hypothesis that there is one independent genetic effect at this locus.
Variants at 1p13, 5q23, 10p12, 11q13, 11q14, and 21q22 demonstrated suggestive genetic 
association with EoE (p < 10−7) (Table 1, Figure 1, Supplementary Figure 5). After 
establishing statistical associations between genetic variants at these loci and EoE, we 
performed fine-mapping studies starting with imputation variants not captured in the 
combined GWAS dataset (Figure 1, Supplementary Figure 3). The 11q13 region has been 
associated with asthma19,20, atopic dermatitis21–24, inflammatory bowel disease25, allergic 
rhinitis26, and sensitization to grass26. The EoE-associated variants at 11q13 are between 
C11orf30 (chromosome 11 open reading frame 30) and LRRC32 (leucine-rich repeat 
containing 32, also known as GARP). LRRC32 has a role in latent transforming growth 
factor beta (TGF)-β surface expression27, and LRRC32 mRNA is highly expressed in 
activated forkhead box P3 (FOXP3)+ T regulatory cells. Notably, TGF-β and FOXP3+ T 
regulatory cells have been implicated in EoE28–32.
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CAPN14 encodes for calpain 14, a calcium-activated cysteine protease. A survey of 130 
tissues revealed that CAPN14 was most highly expressed in the esophagus (Figure 2a, 
Supplementary Figure 5). When we assessed the expression of the calpain family members 
in biopsies from subjects with and without EoE, we found a distinct pattern for control, 
treated EoE, and untreated EoE subjects; Importantly, CAPN14 was dynamically expressed 
as a function of disease activity (Figure 2b). CAPN14 showed the largest upregulation 
compared with all members of the CAPN family (Figure 2b), but three of the other fifteen 
family members, CAPN3, CAPN5, and CAST (calpastatin), were also dysregulated in EoE 
esophageal biopsies (Figure 2b). CAST is a calpain inhibitor and was downregulated (29%, 
p < 10−4). We found a >2-fold increase in CAPN14 expression in the esophageal biopsies of 
patients with active EoE (Figure 2c). Furthermore, IL-13 stimulation of primary esophageal 
epithelial cells and an esophageal epithelial cell line grown at the air-liquid interface with 
IL-13 resulted in a 4-fold and >100-fold increase in CAPN14 expression, respectively 
(Figure 2d, g). Patients with the risk haplotype expressed 30% lower CAPN14 mRNA than 
those without the risk allele (p < 10−2) (Figure 2e).
To identify the genomic mechanisms that may underlie the 2p23 association with EoE, we 
performed chromatin immunoprecipitation sequencing (ChIP-seq) on esophageal epithelial 
cells treated with IL-13. Of the six SNPs most highly associated at the CAPN14 locus after 
imputation, two (rs76562819 and rs75960361) were located in putative regulatory regions 
on the basis of the IL-13–induced H3K27Ac ChIP-seq marks of esophageal epithelial cells, 
as well as publically available ENCODE functional genomics data (including histone marks, 
DNaseI hypersensitivity data, and ChIPseq data)33–35 (Figure 2h).
rs76562819 is located proximal to the 5′ of the CAPN14 transcription start site (Figure 2h), 
lies within a region of elevated H3K4Me1 histone marks in multiple cells lines, and 
intersects with open chromatin regions in 34 cell types on the basis of DNaseI 
hypersensitivity site mapping data. We subsequently performed an electrophoretic mobility 
shift assay (EMSA) using a capture probe from this region and found that the risk allele 
(rs7462819) preferentially bound to a nuclear protein complex compared to the non-risk 
allele (Figure 2i).
Importantly, CAPN14 was the only CAPN family member to be upregulated as measured by 
microarray and RNA sequencing (RNA-seq) in either primary epithelial cells from 
esophageal biopsies and in the organotypic culture after treatment with IL-13 (Figure 3a), 
consistent with previous preliminary findings in other cell types36,37. IL-13 increased 
calpain activity in esophageal epithelial cells treated with IL-13, and this activity was 
inhibited by a calpain specific inhibitor (Figure 3b).
We searched for proximal (cis-acting) expression quantitative trait loci (eQTLs) using gene 
expression data obtained from six cell types or tissues (white blood cells [WBCs], 
lymphoblastoid cell lines, whole blood, adipose tissue, B cells, and monocytes). At two of 
the ten most highly associated EoE risk loci, the sentinel SNP was associated (p < 10−3) 
with the expression of one or more nearby genes. Specifically, the most highly associated 
variants at 1p13 and 8p23 were strongly associated with the expression of the nearest genes 
SLC25A24 (solute carrier family 25 [mitochondrial carrier; phosphate carrier], member 24; p 
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= 1.25×10−9) and XKR6 (p = 1.02×10−7) (Supplementary Table 5). From our own 
expression databases, we have previously reported that TSLP expression is upregulated in 
the biopsies of EoE patients in an allele-dependent manner and in esophageal epithelial cell 
lines treated with polyinosinic:polycytidylic acid9,10.
We measured the RNA-seq expression of all genes within 25 kb of variants with combined p 
< 10−4. Of these 208 genes, 48% were expressed in the esophagus at appreciable levels38; 
this represented an enrichment compared with the expression of the whole genome in the 
esophagus (p < 10−4 using permutation testing). Furthermore, differential expression of 
these genes was sufficient to segregate EoE cases from controls, and 8% of the genes near 
the most highly associated EoE risk loci were differentially expressed (>2-fold average 
change, Bonferroni adjusted p < 5×10−2) in EoE patient vs. control biopsies (Figure 4, 
Supplementary Figure 6). Therefore, these data demonstrate a concentration of EoE 
susceptibility loci in the neighborhood of genes expressed and/or dysregulated in the 
esophagus of diseased patients, suggesting an esophageal functional role for the implicated 
gene. We assessed the GWAS associations for differential H3K27Ac marks in epithelial 
cells after IL-13 treatment. Notably, CAPN14 was one of two genes with these IL-13–
responsive epigenetic characteristics (Supplementary Figure 7). This analysis further 
underscores the potential centrality of CAPN14 in the etiology of EoE. These data are 
consistent with the mechanistic model in which CAPN14 is dynamically expressed in the 
esophagus in response to inflammatory stimuli, a regulatory mechanism disrupted by the 
decreased expression associated with the risk haplotype (Supplementary Figure 8).
The previous genome-wide study of EoE did not assess the most significant variant in 
CAPN14 but did identify suggestive association (p < 10−4) from variants in the region9. 
With additional EoE cases and controls, the current study was better powered to identify 
statistically significant association of genetics variants with the development of EoE. A 
limitation of this study is the lack of a replication stage for those loci that are most highly 
associated with EoE in the combined analysis of the two independent cohorts that were 
assessed. As such, apart from the association at TSLP/WDR36 and CAPN14, other highly 
associated loci remain suggestive until confirmed in subsequent studies.
Two recent GWAS reported 22 loci associated with allergic sensitization39,40. Remarkably, 
we found EoE association at 9 of these 22 loci (Supplementary Table 6), underscoring the 
key role of atopy in EoE, and 8 of these SNPs were associated with comparable disease risk 
effects. The atopic sensitization loci with the greatest association with EoE were at 
CLEC16A, LRRC32, LPP (C-type lectin domain family 16, member A, Leucine rich repeat 
containing 32, LIM domain containing preferred translocation partner in lipoma), and TSLP/
WDR36 (Figure 1, Supplementary Figure 9). However, of the ten loci that were linked with 
EoE in our study, only two overlapped with the 22 allergic sensitization loci, highlighting 
that non-atopy–related processes may be operational.
In conclusion, herein we have increased the number of putative susceptibility loci for EoE 
from one to four and present compelling evidence for six other loci. Importantly, our data 
substantiate a mechanism to elucidate the tissue-specific manifestations of this prototypic 
allergic disease. In particular, we provide additional evidence of shared genetic and 
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molecular pathways between general atopy risk factors (e.g. TSLP/WDR36, LRR32, IL-33, 
LPP) and EoE disease–specific elements, most notably genetic risk factors present at 2p23 
where CAPN14 is located. Consistent with this model, the CAPN14 gene is located in a 
baseline epigenetic hotspot that is modified by IL-13, and CAPN14 is specifically expressed 
in esophageal epithelium and is dynamically upregulated as a function of disease activity 
and genetic haplotype and after exposure of epithelial cells to IL-13. It has not escaped our 
attention that mutations in CAPN3, whose gene product is specifically expressed in skeletal 
muscle, have been associated with susceptibility to another tissue-specific eosinophilic 
disorder (eosinophilic myositis)41–46. Although we do not yet know the molecular steps that 
link calpainopathy to eosinophilic responses, it is notable that CAPN14 belongs to the 
classical calpain sub-family that comprises one of the major proteolytic systems that mediate 
protein cleavage (in addition to the proteasome, lysosome, and caspase systems)47. Classical 
calpains are calcium regulatory proteases and their substrates include structural proteins, 
signaling molecules, transcription factors48,49, and inflammatory mediators that are germane 
for allergic responses, such as STAT-6 (signal transducer and activator of transcription 6) 
and IL-3350,51, the latter of which shows some linkage with EoE (Supplementary Figure 7, 
Table 2). On the basis of the collective data, we propose a model that links the interplay of 
allergic sensitization with an EoE-specific, IL-13–inducible esophageal response involving 
CAPN14.
Data access
The genotyping data from this study have been submitted to dbGAP under the accession 
number phs000494.v1.p1. The expression data from this study have been submitted to the 
NCBI GEO database accession number #.
Methods
Genotyping
Genotyping was performed on the Illumina OMNI-5 and OMNI-2.5 genotyping arrays 
(Illumina) using Infinium2 chemistry. Genotypes were called using the Gentrain2 algorithm 
within Illumina Genome Studio.
Subjects
The study was approved by the Institutional Review Boards at Cincinnati Children’s 
Hospital Medical Center (CCHMC) and all participating sites that were part of the NIH 
Consortium of Food Allergy Research EoE Cohort (Mount Sinai Medical Center, University 
of North Carolina, Johns Hopkin’s University, University of Colorado Health Center/
National Jewish Research Center, and Arkansas Children’s Hospital). Parental informed 
consent was obtained from all participants in this study for the purpose of DNA collection 
and genotyping. Cases were confirmed by a physician to fulfill the diagnostic criteria for 
EoE. EoE is defined as peak eosinophil count ≥15 eosinophils / high-power field in 
esophageal biopsy sections; 30% of CCHMC and 51% of CoFAR patients had PPI therapy 
before the diagnostic endoscopy. Control subjects (non-EoE) included the self-reported 
Caucasian subjects in the Cincinnati Genomic Control Cohort CCHMC (n = 831, age range 
Kottyan et al. Page 6













2–18 years)54, and an external control cohort (non-EoE) acquired from a database of 
Genotypes and Phenotypes (dbGAP) University of Michigan study (n = 8,580). In the 
CCHMC and CoFAR cohorts, 73% and 62% of EoE patients were male, respectively, and 
EoE patients had an age range of 2–52 years. The external control cohort was collected 
through an aging and retirement study; these subjects were significantly older than the cases 
at the time of DNA collection. The subjects in the external control cohort were randomly 
assigned to the CCHMC or CoFAR analysis with the goal of equivalent case:control ratios 
in each cohort.
Population Stratification
Genome-wide data were used to infer the top six principal components of genetic variation 
and correct for possible population stratification using Eigensoft. All local cases and 
controls were self-identified as having European ancestry, and principal component analysis 
was used to exclude all subjects (n = 271) who segregated more than 4 standard deviations 
outside of the mean of the first 4 principal components. Specifically, we removed 34 genetic 
outliers from 736 EoE cases, 13 from 235 CoFAR cases, 71 of 831 CCHMC controls, and 
166 of 8,652 dbGAP University of Michigan controls. The resulting genomic inflation factor 
was 1.001 in a set of ancestral informative markers not including the associated loci. The 
genome-wide genomic inflation seen in our study for the CCHMC cohort and CoFAR 
cohorts were 1.04 and 1.05, respectively.
Genotyping Quality Control
To confirm accurate genotyping and sample identification, we performed an identity-by-
state analysis on a subset of 10,732 SNPs that were genotyped on both the Illumina OMNI-5 
and the previous GWAS platform (Illumina 550)9 and found 99.998% concordance between 
the 134 samples that were genotyped on both platforms. The genome-wide genotyping datat 
was deposited into dbGAP (study Accession: phs00494.v1.p1). Of the original 4,301,332 
markers on the OMNI-5, 2,512,766 were derived from rare variants (<1% MAF). Notably, 
87,539 markers had a suboptimal call rate (e.g. <96%), and 44,246 were not in Hardy 
Weinberg Equilibrium in the controls (p < 10−4). We assessed the most significant 10,000 
variants in Genome-Studio projects that included the locally genotyped cases and controls 
and the external controls from dbGAP; upon visual inspection, 124 of these SNPs did not 
cluster properly and were removed from further analysis. rs8041227 reached genome-wide 
significance; however, no other SNPs around this variant in the dataset were strongly 
associated. The Genome-Studio cluster plot of this particular SNP is given in Supplementary 
Figure 11. External controls were genotyped on the OMNI-2.5, and overlapping variants that 
passed the quality measures described above in both datasets were analyzed. We controlled 
for the presence of potential batch effects in the analysis of the CoFAR samples, by removal 
of SNPs that exhibited outlier fluorescence associated with deviation between plates 
(P<10-4), as per the manufacturer’s recommendation. The final genotyping rate for all SNPs 
was 99.7%. After applying the above filters, we used genotypes from 1,468,075 autosomal 
SNPs in a CCHMC cohort of 435 cases and 716 well-phenotyped local controls from 
CCHMC and 5,776 controls from the dbGAP study and a CoFAR cohort of 222 cases from 
the NIH CoFAR EoE cohort and 2,804 controls from the University of Michigan Health and 
Retirement System (obtained from dbGAP) (Supplementary Table 1).
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Association and Linkage Disequilibrium Analysis
After removing genetic outliers, we performed a logistic regression to calculate p values and 
odds ratios for each SNP using PLINK55 with gender as a co-variant. For some analyses, 
atopy and the most significant SNP in the region were also used as covariates. For analyses 
that used atopy as a covariate, only subjects with known atopic status (EoE cases and local 
Cincinnati controls) were included. For cases, atopy was defined by a physician-documented 
history of positive skin-prick test, allergic rhinitis, allergic dermatitis/eczema, asthma, or 
food allergy. The prevalence of atopy for the local CCHMC and CoFAR EoE cohorts was 
96.2% and 91.3%, respectively. For the Cincinnati Genomic Control Cohort, atopy was 
defined as parent-reported history of allergic rhinitis, eczema, asthma, or food allergy; the 
atopy prevalence of this cohort was 28.6%. LocusZoom56 and R were used to map the 
associated loci in the context of chromosomal recombination and nearby genes.
Imputation to the 1,000 Genomes Reference Panel
To detect associated variants that were not directly genotyped, we imputed highly associated 
regions with IMPUTE2 and used a composite imputation reference panel of integrated 
haplotypes from the 1,000 Genomes Project sequence data freezes from March 2012 
produced using SHAPIT217,18. Imputed genotypes were required to meet or exceed a 
probability threshold of 0.9, an information measure of >0.4, and the same quality-control 
criteria threshold described for the genotyped markers.
Expression Analysis
Quantitative real-time PCR analysis was performed on cDNA from distal esophageal biopsy 
RNA. EoE biopsies showed active disease pathology at the time when they were taken, and 
all patients reported no glucocorticoid treatment at the time of biopsy, except for the analysis 
of gene expression as a function of disease activity in which remission was defined after 
glucocorticoid therapy. Statistical testing for mRNA expression normalized to GAPDH 
(glyceraldehyde 3-phosphate dehydrogenase) was determined by Mann-Whitney U test 
using GraphPad Prism software.
Expression Microarray Analysis
For each patient, 1 distal esophageal mucosal biopsy sample was immersed in RNAlater 
RNA stabilization reagent (QIAGEN) and stored at 4°C for less than 15 days. Total RNA 
was extracted using RNeasy Mini Kit (QIAGEN) according to the manufacturer’s 
recommendations. Hybridization to DNA microarray was performed by the Microarray Core 
at CCHMC, as previously reported13,57. The genome-wide human Affymetrix U133 Plus 2.0 
GeneChip was used, and gene transcript levels were determined using algorithms in the 
Microarray Analysis Suite and GeneSpring software (Silicon Genetics).
RNA Sequencing
Esophageal biopsy RNA was isolated from EoE patients with active disease and from 
unaffected controls as previously described13,38. RNA sequencing acquiring 10 million 
mappable 100 base-pair reads from paired-end libraries was performed at the Genetic 
Variation and Gene Discovery Core Facility at CCHMC. Data were aligned to the GrCh37 
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build of the human genome using the Ensembl58 annotations as a guide for TopHat59. 
Expression analysis was performed using Cufflinks60. Data were visualized using the 
Integrative Genomics Viewer (Broad Institute). Enrichment analysis was performed using 
permutation testing by randomly selected SNPs from the chip, identified the nearest gene 
and assessed the number of genes expressed in the esophagus. Only 10 permutations out of 
100,000 total permutations had more than or equal to 99 genes expressed in the esophagus.
Electrophoretic Mobility Shift Assay (EMSA)
Pairs of single-stranded 5′ IRDye infrared dye labeled and unlabeled oligonucleotides 
(obtained from IDT Inc, Coralville, Iowa, USA) were annealed to generate double-stranded 
probes. Twenty-five to 50 fmoles of labeled probes was incubated with 8 or 10 μg of nuclear 
extract prepared from esophageal cell line TE-7, 6 μg poly (deoxyinosinic-doxycytidylic) 
acid, and 1 μl salmon sperm provided along with the buffers and protocols supplied with the 
Odyssey Infrared EMSA kit (LI-COR Biosciences, Lincoln, Nebraska, USA). The binding 
reactions were analyzed using electrophoresis on 6% Tris-Borate-EDTA polyacrylamide 
gels and detected by an infrared fluorescent procedure using the Odyssey Infrared Imaging 
System (LI-COR Biosciences, Lincoln, Nebraska, USA)
Organotropic Cultures
For the air-liquid interface (ALI) culture system, the esophageal epithelial cell line (hTERT-
immortalized EPC2 line from Dr. Anil Rustgi [University of Pennsylvania]) was grown to 
confluence on 0.4 μm pore–size polyester permeable supports (Corning Incorporated, 
Corning, NY) in keratinocyte serum-free media (K-SFM) (Life Technologies, Grand Island, 
NY) supplemented with 1.8 mM calcium. Epithelial differentiation was then induced by 
removing culture media from the inner chamber of the permeable support and maintaining 
the esophageal epithelial cells for 5–7 days at the ALI in the presence or absence of IL-13 
(100 ng/mL).
H3K27Ac Analysis
Ten to 20 million TE-7 cells were fixed with 0.8% formaldehyde by adding 1 ml of 10X 
fixation buffer (50 mM HEPES-KOH, pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5 mM 
EGTA, 8% formaldehyde) to 9 ml of growth medium for 8 minutes at room temperature 
with shaking. The reaction was stopped by adding glycine to a final concentration of 125 
mM for an additional 5 minutes. Nuclei were prepared with truChIP™ High Cell Chromatin 
Shearing Kit with SDS Shearing Buffer (Covaris) according to manufacturer 
recommendations. Sonication was performed using a Covaris S220 Focused ultrasonicator at 
175 pip, 10% output, 200 bursts for 8 minutes. Efficient DNA fragmentation was verified by 
agarose gel electrophoresis. ChIP was performed with 2 μg of H3K27Ac antibody (ab4729, 
Abcam) in SX-8G IP-Star® Automated System (Diagenode) in RIPA buffer (TE+0.1% 
SDS, 1% Triton X-100, 150 mM NaCl, 0.1% Sodium Deoxycholate) following the protocol 
of the manufacturer. Fastq files from Illumina pipeline were aligned by bowtie (version 
1.0.0)61 and unique reads were identified with no more than one error allowed for 
alignment. MACS2 (version 2.0.10.20130712)62 was used to identify islands of enrichment 
(q-value threshold less than 0.2) and estimated fragment size. For visualization, data were 
uploaded to the University of California, Santa Cruz genome browser.
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EPC2 cultures were treated with or without IL-13 (100 ng/mL) for 48 hours and lysed with 
Mammalian Protein Extraction Reagent lysis buffer (Pierce, #78501) in the presence of 
1mM ethylenediaminetetraacetic acid and 1mM dithiothreitol on ice. Calpain activity was 
measured with the Promega Calpain-Glo protease assay according to the manufacturer’s 
instructions. Briefly, 50 μl of lysate was incubated for 10 minutes with reaction buffer and +/
− 100 mM PD150606 (Santa Cruz, s-222133) and luminescence was read using the Biotek 
Synergy2 Multi-Mode Microplate reader.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We kindly thank the participants and their families. This study would not be possible without the CoFAR site 
investigators: Scott H. Sicherer, MD; Stacie M. Jones, MD; Tamara T. Perry, MD; Amy Scurlock, MD; Edwin 
Kim, MD; Evan Dellon, MD, MPH; A. Wesley Burks, MD; Glenn T. Furuta, MD; Donald Y.M. Leung, MD, PhD; 
and Donald Stablein, PhD. Other people who contributed to this study include Jessica Gau, RN, PNP; Jaclyn 
Fronda, BA; Diane Ananos, RN; Kim Mudd, RN, BSN, MS; Thomas Fitzgerald, BS; Peggy Chandler, APN; Erin 
O’Brien, BS; Suzanne Carlisle, RN; Anne Hiegel, RN; Pam Steele, BSN; Jessica Gebhart, MSHS; Deanna 
Hamilton, RN; Wendy Moore MS; JoAnne Newton RN; Susan Leung, RN; Donna Brown; Marshall Plaut, MD; 
and Julian Poyser, MPA, MS, CRNP.
Funding for this project was provided by the NIH, NIAID, NIDDK, NHLBI, and NHGRI (U19 AI066738, U01 
HG006828, U01 HG006828-S1, U01 HG006828-S2, U01 AI066560, R37 AI024717, P01 AI083194, T32 
HL7752-19, K23 AI099083 and P01 AR049084). The CoFAR arm of the study was supported by NIH U19 
AI066738 by NIAID and NIDDK. The project was also supported by several grants from the National Center for 
Research Resources (NCRR), a component of the NIH: UL1 TR001082 (National Jewish), UL1 TR-000067 
(Mount Sinai), UL1 TR-000039 (Arkansas), UL1 TR-000083 (U North Carolina), and UL1 TR-000424 (Johns 
Hopkins). Support was also received from the US Department of Veteran Affairs IMMA 9, and the Department of 
Defense (PR094002). This research was supported in part by the Cincinnati Children’s Research Foundation and its 
Cincinnati Genomic Control Cohort. Other support was derived from, the Campaign Urging Research For 
Eosinophilic Diseases (CURED), Buckeye Foundation, Food Allergy Research Education (FARE) foundation, and 
the Foundation of the American College of Allergy, Asthma, and Immunology.
We thank Shawna Hottinger for editorial assistance.
References
1. Liacouras CA, et al. Eosinophilic esophagitis: updated consensus recommendations for children and 
adults. J Allergy Clin Immunol. 2011; 128:3–20. e6. quiz 21–2. [PubMed: 21477849] 
2. Rothenberg ME. Biology and treatment of eosinophilic esophagitis. Gastroenterology. 2009; 
137:1238–49. [PubMed: 19596009] 
3. Collins MH, et al. Clinical, pathologic, and molecular characterization of familial eosinophilic 
esophagitis compared with sporadic cases. Clin Gastroenterol Hepatol. 2008; 6:621–9. [PubMed: 
18434257] 
4. Putnam PE, Rothenberg ME. Eosinophilic esophagitis: concepts, controversies, and evidence. Curr 
Gastroenterol Rep. 2009; 11:220–5. [PubMed: 19463222] 
5. Abonia JP, Rothenberg ME. Eosinophilic esophagitis: rapidly advancing insights. Annu Rev Med. 
2012; 63:421–34. [PubMed: 22034864] 
6. Davis BP, Rothenberg ME. Emerging concepts of dietary therapy for pediatric and adult 
eosinophilic esophagitis. Expert Rev Clin Immunol. 2013; 9:285–7. [PubMed: 23557262] 
7. Henderson CJ, et al. Comparative dietary therapy effectiveness in remission of pediatric 
eosinophilic esophagitis. J Allergy Clin Immunol. 2012; 129:1570–8. [PubMed: 22541246] 
Kottyan et al. Page 10













8. Rothenberg ME, et al. Working with the US Food and Drug Administration: progress and timelines 
in understanding and treating patients with eosinophilic esophagitis. J Allergy Clin Immunol. 2012; 
130:617–9. [PubMed: 22935588] 
9. Rothenberg ME, et al. Common variants at 5q22 associate with pediatric eosinophilic esophagitis. 
Nat Genet. 2010; 42:289–91. [PubMed: 20208534] 
10. Sherrill JD, et al. Variants of thymic stromal lymphopoietin and its receptor associate with 
eosinophilic esophagitis. J Allergy Clin Immunol. 2010; 126:160–5. e3. [PubMed: 20620568] 
11. Zuo L, et al. IL-13 induces esophageal remodeling and gene expression by an eosinophil-
independent, IL-13R alpha 2-inhibited pathway. J Immunol. 2010; 185:660–9. [PubMed: 
20543112] 
12. Blanchard C, et al. Coordinate interaction between IL-13 and epithelial differentiation cluster 
genes in eosinophilic esophagitis. J Immunol. 2010; 184:4033–41. [PubMed: 20208004] 
13. Blanchard C, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic 
esophagitis. J Clin Invest. 2006; 116:536–47. [PubMed: 16453027] 
14. McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy 
Clin Immunol. 2013; 131:280–91. [PubMed: 23374260] 
15. Fallon PG, et al. A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced 
percutaneous allergen priming. Nat Genet. 2009; 41:602–8. [PubMed: 19349982] 
16. Shin HD, et al. Association of Eotaxin gene family with asthma and serum total IgE. Hum Mol 
Genet. 2003; 12:1279–85. [PubMed: 12761043] 
17. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-
wide association studies by imputation of genotypes. Nat Genet. 2007; 39:906–13. [PubMed: 
17572673] 
18. Altshuler DM, et al. Integrating common and rare genetic variation in diverse human populations. 
Nature. 2010; 467:52–8. [PubMed: 20811451] 
19. Ferreira MA, et al. Identification of IL6R and chromosome 11q13.5 as risk loci for asthma. Lancet. 
2011; 378:1006–14. [PubMed: 21907864] 
20. Tang HY, et al. Association analysis of single nucleotide polymorphisms at five loci: comparison 
between atopic dermatitis and asthma in the Chinese Han population. PLoS One. 2012; 7:e35334. 
[PubMed: 22545103] 
21. Esparza-Gordillo J, et al. A common variant on chromosome 11q13 is associated with atopic 
dermatitis. Nat Genet. 2009; 41:596–601. [PubMed: 19349984] 
22. Greisenegger EK, Zimprich F, Zimprich A, Gleiss A, Kopp T. Association of the chromosome 
11q13.5 variant with atopic dermatitis in Austrian patients. Eur J Dermatol. 2013
23. Hirota T, et al. Genome-wide association study identifies eight new susceptibility loci for atopic 
dermatitis in the Japanese population. Nat Genet. 2012; 44:1222–6. [PubMed: 23042114] 
24. Paternoster L, et al. Meta-analysis of genome-wide association studies identifies three new risk loci 
for atopic dermatitis. Nat Genet. 2012; 44:187–92. [PubMed: 22197932] 
25. Barrett JC, et al. Genome-wide association defines more than 30 distinct susceptibility loci for 
Crohn’s disease. Nat Genet. 2008; 40:955–62. [PubMed: 18587394] 
26. Ramasamy A, et al. A genome-wide meta-analysis of genetic variants associated with allergic 
rhinitis and grass sensitization and their interaction with birth order. J Allergy Clin Immunol. 
2011; 128:996–1005. [PubMed: 22036096] 
27. Tran DQ, et al. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on 
platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A. 2009; 106:13445–
50. [PubMed: 19651619] 
28. Fuentebella J, et al. Increased number of regulatory T cells in children with eosinophilic 
esophagitis. J Pediatr Gastroenterol Nutr. 2010; 51:283–9. [PubMed: 20639775] 
29. Stuck MC, Straumann A, Simon HU. Relative lack of T regulatory cells in adult eosinophilic 
esophagitis - no normalization after corticosteroid therapy. Allergy. 2011; 66:705–7. [PubMed: 
21470243] 
Kottyan et al. Page 11













30. Tantibhaedhyangkul U, Tatevian N, Gilger MA, Major AM, Davis CM. Increased esophageal 
regulatory T cells and eosinophil characteristics in children with eosinophilic esophagitis and 
gastroesophageal reflux disease. Ann Clin Lab Sci. 2009; 39:99–107. [PubMed: 19429794] 
31. Zhu X, Wang M, Crump CH, Mishra A. An imbalance of esophageal effector and regulatory T cell 
subsets in experimental eosinophilic esophagitis in mice. Am J Physiol Gastrointest Liver Physiol. 
2009; 297:G550–8. [PubMed: 19571233] 
32. Frischmeyer-Guerrerio PA, et al. TGFbeta receptor mutations impose a strong predisposition for 
human allergic disease. Sci Transl Med. 2013; 5:195ra94.
33. Maher B. ENCODE: The human encyclopaedia. Nature. 2012; 489:46–8. [PubMed: 22962707] 
34. Ecker JR, et al. Genomics: ENCODE explained. Nature. 2012; 489:52–5. [PubMed: 22955614] 
35. Skipper M, Dhand R, Campbell P. Presenting ENCODE. Nature. 2012; 489:45. [PubMed: 
22955612] 
36. Ueta M, Mizushima K, Yokoi N, Naito Y, Kinoshita S. Expression of the interleukin-4 receptor 
alpha in human conjunctival epithelial cells. Br J Ophthalmol. 2010; 94:1239–43. [PubMed: 
20610477] 
37. Ueta M, Sotozono C, Kinoshita S. Expression of interleukin-4 receptor alpha in human corneal 
epithelial cells. Jpn J Ophthalmol. 2011; 55:405–10. [PubMed: 21617960] 
38. Sherrill JD, et al. Analysis and expansion of the eosinophilic esophagitis transcriptome by RNA 
sequencing. Genes and Immunity. 2014 In Press. 
39. Bonnelykke K, et al. Meta-analysis of genome-wide association studies identifies ten loci 
influencing allergic sensitization. Nat Genet. 2013; 45:902–6. [PubMed: 23817571] 
40. Hinds DA, et al. A genome-wide association meta-analysis of self-reported allergy identifies 
shared and allergy-specific susceptibility loci. Nat Genet. 2013; 45:907–11. [PubMed: 23817569] 
41. Krahn M, et al. Eosinophilic infiltration related to CAPN3 mutations: a pathophysiological 
component of primary calpainopathy? Clin Genet. 2011; 80:398–402. [PubMed: 21204801] 
42. Krahn M, et al. CAPN3 mutations in patients with idiopathic eosinophilic myositis. Ann Neurol. 
2006; 59:905–11. [PubMed: 16607617] 
43. Bartoli M, et al. Validation of comparative genomic hybridization arrays for the detection of 
genomic rearrangements of the calpain-3 and dysferlin genes. Clin Genet. 2012; 81:99–101. 
[PubMed: 22150418] 
44. Brown RH Jr, Amato A. Calpainopathy and eosinophilic myositis. Ann Neurol. 2006; 59:875–7. 
[PubMed: 16718709] 
45. Amato AA. Adults with eosinophilic myositis and calpain-3 mutations. Neurology. 2008; 70:730–
1. [PubMed: 18299526] 
46. Oflazer PS, Gundesli H, Zorludemir S, Sabuncu T, Dincer P. Eosinophilic myositis in 
calpainopathy: could immunosuppression of the eosinophilic myositis alter the early natural course 
of the dystrophic disease? Neuromuscul Disord. 2009; 19:261–3. [PubMed: 19285864] 
47. Sorimachi H, Hata S, Ono Y. Calpain chronicle--an enzyme family under multidisciplinary 
characterization. Proc Jpn Acad Ser B Phys Biol Sci. 2011; 87:287–327.
48. Arnandis T, et al. Differential functions of calpain 1 during epithelial cell death and adipocyte 
differentiation in mammary gland involution. Biochem J. 2014
49. Wang Y, Zhang Y. Regulation of TET Protein Stability by Calpains. Cell Rep. 2014; 6:278–84. 
[PubMed: 24412366] 
50. Meephansan J, Tsuda H, Komine M, Tominaga S, Ohtsuki M. Regulation of IL-33 expression by 
IFN-gamma and tumor necrosis factor-alpha in normal human epidermal keratinocytes. J Invest 
Dermatol. 2012; 132:2593–600. [PubMed: 22673732] 
51. Hayakawa M, et al. Mature interleukin-33 is produced by calpain-mediated cleavage in vivo. 
Biochem Biophys Res Commun. 2009; 387:218–22. [PubMed: 19596270] 
52. Wu C, et al. BioGPS: an extensible and customizable portal for querying and organizing gene 
annotation resources. Genome Biol. 2009; 10:R130. [PubMed: 19919682] 
53. McCall MN, Uppal K, Jaffee HA, Zilliox MJ, Irizarry RA. The Gene Expression Barcode: 
leveraging public data repositories to begin cataloging the human and murine transcriptomes. 
Nucleic Acids Res. 2011; 39:D1011–5. [PubMed: 21177656] 
Kottyan et al. Page 12













54. Prahalad S, et al. Juvenile rheumatoid arthritis: linkage to HLA demonstrated by allele sharing in 
affected sibpairs. Arthritis Rheum. 2000; 43:2335–8. [PubMed: 11037894] 
55. Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage 
analyses. Am J Hum Genet. 2007; 81:559–75. [PubMed: 17701901] 
56. Pruim RJ, et al. LocusZoom: regional visualization of genome-wide association scan results. 
Bioinformatics. 2010; 26:2336–7. [PubMed: 20634204] 
57. Zimmermann N, et al. Dissection of experimental asthma with DNA microarray analysis identifies 
arginase in asthma pathogenesis. J Clin Invest. 2003; 111:1863–74. [PubMed: 12813022] 
58. Flicek P, et al. Ensembl 2013. Nucleic Acids Res. 2013; 41:D48–55. [PubMed: 23203987] 
59. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. 
Bioinformatics. 2009; 25:1105–11. [PubMed: 19289445] 
60. Trapnell C, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated 
transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010; 28:511–5. 
[PubMed: 20436464] 
61. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short 
DNA sequences to the human genome. Genome Biol. 2009; 10:R25. [PubMed: 19261174] 
62. Zhang Y, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008; 9:R137. 
[PubMed: 18798982] 
Kottyan et al. Page 13













Figure 1. Manhattan plot of the p values obtained from the genome-wide association analysis
a. Data are from 736 subjects with EoE and 9,246 controls having 1,468,075 genetic 
variants, with minor allele frequencies greater than 1% in the subjects with EoE. The −log of 
the probability is shown as a function of the genomic position of the autosomes. Genome-
wide significance (red dotted line, p ≤ 5×10−8) and suggestive significance (solid blue line, p 
≤ 10−7) are indicated. b–e. Genetic association of variants at the 2p23, 5q22, 8p23, and 
15q13 loci with EoE risk. P values (−log10) of the genetic association analysis of genotyped 
and imputed variants are plotted against the genomic positions of each genotyped (blue) and 
imputed (red) SNPs on the x axis on chromosomes 2, 5, 8, and 15. Genes in the region are 
shown above. The black lines indicate the recombination rates in cM per Mb using subjects 
of European Ancestry from the 1,000 genomes project.
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Figure 2. CAPN14 is specifically expressed in esophageal epithelium, dynamically upregulated as 
a function of disease activity and genetic haplotype and after exposure of epithelial cells to IL-13
a. Barcode Z-score relative microarray expression of CAPN14 in various human tissue 
samples. Barcode analysis of 18,656 publically available microarrays as displayed by 
biogps.org52,53. Representative data from multiple cellular subtypes. Error bars represent the 
median absolute deviation. (Refer to Supplemental Figure 2 for an exhaustive list). b. 
Microarray expression heat map of calpain family in esophageal biopsies from normal 
controls (NL, n = 14), therapy-responsive EoE patients (EoE remission, n = 18), active EoE 
patients (EoE active, n = 18), and therapy-non-responsive EoE patients (EoE resistant, n = 
19). c. Microarray expression analysis of CAPN14 expression from esophageal biopsies 
(NL, n = 14; EoE active, n = 18; EoE inactive, n = 18) (b. and c.) and primary esophageal 
epithelial cells with or without IL-13 stimulation for 48 hours (d). Error bars represent 
standard error of the mean (s.e.m.), n=3. e. Real-time PCR analysis of CAPN14 expression 
in biopsies from EoE patients with the non-risk haplotype (n = 19) or with at least one copy 
of the risk haplotype at the 2p23 loci (n = 17). The risk haplotype is defined as having the 
EoE risk allele (highlighted in red) at each of the six most highly associated variant 
locations. Error bars represent s.e.m. f. Schematic of esophageal epithelial air-liquid 
interface (ALI) transwell culture system and H&E staining demonstrating stratification. g. 
RNA-seq expression analysis of CAPN14 expression from ALI cultures with or without 
IL-13 stimulation for 6 days (n = 3 for each group). Error bars represent s.e.m. h. Chip-seq 
on TE-7 cells shows increased H3K27Ac marks with IL-13 stimulation over the 
transcriptional start site of CAPN14, which correlates with an increase in transcriptional 
activity by RNA-seq. One significantly associated SNP (rs76562819) is in this acetylation 
region. i. EMSA was used to probe nuclear lysates from an esophageal epithelial cell line 
using oligonucleotides with the risk [G] or non-risk [A] allele of rs7656219.
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Figure 3. IL-13 induces CAPN14 expression and calpain activity
a. Heat map of microarray expression of the calpain family in primary esophageal epithelial 
cell culture (left) and in EPC2 air-liquid interface cultures (right). b. Calpain activity assay 
in EPC2 cells with or without IL-13 stimulation for 48 hours in the presence or absence of 
the calpain inhibitor PD150606. Error bars represent s.e.m. Error bars represent s.e.m. (data 
representative of 3 independent experiments)
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Figure 4. Genes at EoE risk loci with differential expression in biopsies from EoE patients 
compared to controls
Genes within 25 kb of the 768 genetic variants associated with EoE (combined p < 10−4) 
were used in this analysis of RNA-seq data. The expression of 208 genes was assessed. 
Normalized fold-change is shown for all genes with 2-fold average change and corrected p < 
0.05. NL, normal controls.
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